Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lenvima/Keytruda Combo Cuts Risk of Death by 38% in Endometrial Cancer
March 22, 2021
- KM Biologics Begins Formulation of AstraZeneca’s COVID-19 Vaccine
March 22, 2021
- Takeda’s OTC Unit to Be Renamed Alinamin with New Chief from Blackstone
March 22, 2021
- Nippon Shinyaku Gets Japan Rights to Menarini’s Blood Cancer Med
March 19, 2021
- Takeda Rolls Out Music App to Encourage Exercise for Parkinson’s Patients
March 18, 2021
- PII Study Now underway for StemRIM’s Redasemtide for Chronic Liver Disease
March 18, 2021
- Medicago/GSK Begins PIII for COVID-19 Vaccine, Mitsubishi Mum on Japan Plan
March 18, 2021
- Eisai, German Institute Link Arms on Neurodegenerative Disorder Research
March 18, 2021
- Torii Gets Japan Rights to Verrica’s Wart Drug
March 18, 2021
- Shionogi Curbing Supplies of Claritin Dry Syrup after Alesion Recalls
March 18, 2021
- Sawai Reaches Settlement over Doping Substance Contamination Lawsuit
March 18, 2021
- Fujifilm Invests 100 Million Yen in Cell Therapy Startup Cuorips
March 17, 2021
- Eisai’s Anti-Tau Antibody Picked for US Prevention Trial for Inherited Alzheimer’s
March 17, 2021
- CureApp Hypertension Therapeutic App Hits PIII Goal, 2021 Submission Eyed
March 17, 2021
- Morimoto Pharma Looking to Partner with Drug Makers, CMOs to Develop Freeze-Dried COVID Vaccines in Japan
March 17, 2021
- Otsuka Grabs Japan Rights to Perception’s Antidepressant
March 17, 2021
- Nippon Shinyaku Taps Global-Savvy Toru Nakai as New President
March 17, 2021
- Takeda Pitches In Production Capacities for J&J’s COVID-19 Vaccine
March 17, 2021
- Quake-Halted Nipro Plant Affecting Supplies of Pfizer, Espha Generics
March 17, 2021
- Alesion Dry Syrup, Generics Pulled from Shelves over Mutagenic Impurities
March 16, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…